Slide 1: Cencora, Inc. Third Quarter Fiscal 2025 Earnings Call
Cencora, Inc. Third Quarter Fiscal 2025 Earnings Call August 6, 2025
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our purpose: We are united in our responsibility to create healthier futures We use our global reach and local community expertise to connect patients to pharmaceuticals through strategic partnerships with manufacturers and healthcare providers. Gro
Slide 4: Third quarter highlights & strategic overview
Third quarter highlights & strategic overview Company highlights Financial highlights & fiscal 2025 guidance • In July 2025, Good Neighbor Pharmacy, Cencora’s national • Adjusted diluted EPS(1) increased 19.8% year-over-year to $4.00. franchise for independent pharmacies, brought together more than
Slide 5: Financial results
cencora Financial results
Slide 6: Q3 fiscal 2025 financial summary
Q3 fiscal 2025 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $80.7B 8.7% $80.7B 8.7% 8.7% Gross profit $2.9B $2.9B y/y% 20.6% 20.7% Revenue growth y/y 20.6% Operating expenses $2.0B $1.8B Consolidated y/y% 17.3% 20.8% adjusted operating income(1) growth y/y Operatin
Slide 7: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Q3 fiscal 2025 financial results Q3 Q3 Financial results y/y% fiscal 2025 fiscal 2024 • Revenue increased 8.5% to $72.9 billion Revenue $72.9B $67.2B 8.5% due to overall market growth primarily driven by unit volume growth, including increased Operating income $0.9B
Slide 8: International Healthcare Solutions segment
International Healthcare Solutions segment Q3 fiscal 2025 financial results Constant Financial results Q3 Q3 y/y% currency(1) (as reported) fiscal 2025 fiscal 2024 • Revenue of $7.8 billion was up 10.5% on y/y% an as reported basis. On a constant $7.8B $7.1B 10.5% 8.8% currency basis, revenue increa
Slide 9: Fiscal 2025 guidance
cencora Fiscal 2025 guidance =
Slide 10: Fiscal 2025 guidance
Fiscal 2025 guidance As reported Constant currency(1) Consolidated Revenue ~9% Adjusted operating income(1) 15% to 16% U.S. Healthcare Solutions Revenue 9% to 10% Operating income 20% to 21% International Healthcare Solutions Revenue 6% to 7% 7% to 8% Operating income ~(6)% ~(5)% Bold numbers indica
Slide 11: Fiscal 2025 guidance continued
Fiscal 2025 guidance continued Fiscal 2025 Guidance Fiscal 2024 Actual Adjusted diluted earnings per share(1) $15.85 to $16.00 $13.76 Net interest expense $290 to $310 million $157 million Adjusted effective tax rate(1) 20.5% to 21% 20.8% Diluted weighted average shares outstanding 195.0 to 195.5 mi
Slide 12: Advancing corporate responsibility initiatives to create healthier futures
Global Corporate Responsibility Building resilient and sustainable operations • Business Resilience: Performed physical risk assessments using climate models to inform operational planning. • Renewable Energy: World Courier facilities in Stockholm and Copenhagen began generating on-site solar energy
Slide 13: Appendix
cencora Appendix
Slide 14: CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended June 30, 2025 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP $ 2,907,
Slide 15: CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended June 30, 2024 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP $ 2,410,
Slide 16: Supplemental information regarding non-GAAP financial measures
Supplemental information regarding non-GAAP financial measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 17: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) • Adjusted net income attributable to Cencora: Adjusted net income attributable to the Company is a non-GAAP financial measure that excludes the same items that are described above. Management believes that this non-GAAP financia
Slide 18: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations and Treasury Bennett.Murphy@cencora.com 18